The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Rainer Claus
No Relationships to Disclose
 
Francesco Ricci
No Relationships to Disclose
 
Björn Hackanson
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Travel, Accommodations, Expenses - Celgene
 
Christoph Rummelt
No Relationships to Disclose
 
Oliver Fietz
Employment - Boehringer Ingelheim
 
Thomas Arnhold
Employment - Boehringer Ingelheim
 
Dooti Roy
Employment - Boehringer Ingelheim
 
Zohra Oum'Hamed
Employment - Boehringer Ingelheim
 
Ralph M Fritsch
No Relationships to Disclose